Fulgent (FLGT) Narxning foydaga nisbati

Fulgent Corp (FLGT) korporativ emblemasi va logotipi

Fulgent Genetics, Inc. (FLGT) innovatsion dasturiy ta'minot yordamida IT mutaxassislarini jalb qilgan holda, yuqori texnologiyali genetik tahlil muhitini ishlab chiqmoqda. Ushbu GURU.Markets grafigida ko'rsatilganidek, biznesning joriy P/E ko'rsatkichi -7.80 atrofida qolmoqda. Biroq, reagentlarning yetishmasligi va geosiyosat xalqaro testlar o'tkazilishiga to'sqinlik qilmoqda. Klinikalarning sodiqligiga qaramay, vaziyat FDA ning qat'iy nazorati va COVID yuksalishidan keyingi talabning pasayishi bilan yanada murakkablashgan.

FLGT Fulgent Genetics: Narxning foydaga nisbati 04.07.2022 - 12.11.2026 oraligʻida

Fulgent Genetics, Inc. kompaniyasining tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning jamlanma tahlili:fulgentgenetics.com (FLGT)
Fulgent Genetics, Inc. ishlab chiqargan mahsulot

Fulgent Genetics, Inc. (FLGT) uchun xavfsizlik zaxirasini baholashda, P/E koeffitsiyenti biznesning bozor qiymati hosil bo'lgan sof foyda asosida qancha muddatda qoplanishini o'lchashini tushunish muhimdir. Fulgent Genetics, Inc. (FLGT) ning P/E koeffitsiyenti tendentsiyalarini tahlil qilish orqali investor aktivlarning haddan tashqari qimmat baholanganligini aniqlashi mumkin, bu esa import qilinadigan reagentlar yoki diagnostikaning operatsion o'sishini cheklaydigan IT komponentlar yetkazib berish zanjiridagi uzilishlar paytida kritik ahamiyatga ega bo'ladi.

Raqobatdosh kompaniyalar

P/E multiplikatori agilent.com|Narxning foydaga nisbati Quest Diagnostics Incorporated (DGX)|Narxning foydaga nisbati ILMN (Illumina Inc)|Cologuard - Narx-foyda koeffitsiyenti|Revvity Corp (RVTY) - Kapitalizatsiyaning foydaga nisbati|BIO - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati anbio.com NNNN|SHC: P/E multiplikatori|QDEL - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati OPKO Corp|caredx.com (CDNA) - Biznesning o‘zini qoplash muddati|P/E multiplikatori MRVI|LAB: Kapitalizatsiyaning sof foydaga nisbati|Cytek Biosciences - Narx-foyda koeffitsiyenti|P/E multiplikatori OraSure Technologies, Inc. OSUR|XGN - Narxning foydaga nisbati|MDXH: Narxning foydaga nisbati|LUCD: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Prenetics PRE|IMDX (Insight Molecular Diagnostics, Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Trinity Biotech Corp TRIB|Narxning foydaga nisbati ProPhase (PRPH)|Ainos Corporation - Narx-foyda multiplikatori|Co-Diagnostics, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati HSCS (heartsciences.com)|BMRA: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati CDIO (Cardio Diagnostics)|ONCO: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Virax Biolabs Corp VRAX|BJDX (Bluejay Diagnostics) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati aspirawh.com AWH|Narxning foydaga nisbati Accelerate Diagnostics, Inc. (AXDX)|CENTOGENE - Narx-foyda multiplikatori|P/E multiplikatori ENZ (Enzo Biochem)|Fresh2 Group Ltd (FRES) - Kapitalizatsiyaning foydaga nisbati|GENE: Narx-foyda koeffitsiyenti|23andme.com - Bozor narxining sof foydaga nisbati|PMD: P/E multiplikatori